Back to top

biotechs: Archive

Zacks Equity Research

BIAF Stock Dips Post Q3 Earnings Despite Rising Test Demand, Sales Down

bioAffinity's third-quarter 2026 results show weaker laboratory revenues and wider losses despite rising CyPath Lung test demand and growing physician adoption.

BIAFNegative Net Change

Zacks Equity Research

Moderna Issues Cost Outlook Amid Revenue Uncertainty, Stock Falls

MRNA shares fall as 2027 cost projections raise concerns, while limited visibility into future revenue growth weighs on investor sentiment.

MRNAPositive Net Change SNYNegative Net Change PFENegative Net Change MRKNegative Net Change

Zacks Equity Research

CRMD Stock Down 9% Despite Q3 Earnings and Revenues Beat Estimates

CorMedix beats Q3 estimates, but DefenCath pricing pressure hurts sales. Rezzayo progress and the planned Heron acquisition shape its 2027 outlook.

CRMDPositive Net Change ADPTPositive Net Change ACIUPositive Net Change AMRXNegative Net Change

Ahan Chakraborty

4 Key Stocks to Watch Across Diabetes and Obesity This Awareness Day

LLY, NVO, VKTX and GPCR advance diabetes and obesity treatments, with promising drug candidates, expanding clinical studies and key pipeline milestones ahead.

NVONegative Net Change LLYNegative Net Change VKTXNegative Net Change GPCRNegative Net Change

Kevin Cook

Bear of the Day: Boston Scientific (BSX)

BSX growth continues to flatline but expects 2027 to mark cycle's trough, 2028 recovery driven by new launches

BSXNegative Net Change

Sundeep Ganoria

How Did AbbVie's Immunology Franchise Fare in Q3?

ABBV's immunology sales rose 16.6% in Q3, driven by Skyrizi and Rinvoq growth, prompting higher 2026 sales forecasts despite Humira's decline.

ABBVNegative Net Change JNJNegative Net Change LLYNegative Net Change

Sundeep Ganoria

MRNA Stock Up 3% Since Q3 Earnings Release: How to Play the Stock?

Moderna's 3% post-earnings gain reflects stronger overseas COVID-19 sales and higher 2026 guidance, while oncology advances offer growth potential.

MRNAPositive Net Change PFENegative Net Change MRKNegative Net Change BNTXNegative Net Change

Zacks Equity Research

REGN Soars 27.4% in a Month: Buy, Sell or Hold the Stock?

Regeneron's strong Eylea HD and Dupixent sales, expanding oncology portfolio and promising pipeline fuel growth prospects as Eylea faces intensifying competition.

REGNNegative Net Change

Ekta Bagri

Can Gilead Sciences' HIV Business Fuel Sustainable Long-Term Growth?

GILD's HIV franchise gains momentum as Yeztugo sales surge, Biktarvy maintains market leadership and an expanding pipeline strengthens long-term growth prospects.

GILDNegative Net Change GSKNegative Net Change MRKNegative Net Change

Zacks Equity Research

Zoetis' Cytopoint Plus Gets USDA License for 75-Day Canine Itch Relief

ZTS' Cytopoint Plus secures a USDA license, offering dogs with allergic dermatitis 75 days of itch relief and a longer interval between injections.

ZTSNegative Net Change ADPTPositive Net Change ACIUPositive Net Change AMRXNegative Net Change